NUMBERS HAVE POWER.
JOIN THE REGISTRY.
ADVANCE THE SCIENCE.
Together we can find a cure for ftd
The FTD Disorders Registry is a powerful tool in the movement to create therapies and find a cure. Together we can help change the course of the disease and put an end to FTD.
Your privacy is important! We promise to protect it. We will not share your contact information.
WHAT IS THE FTD DISORDERS REGISTRY?
The Registry is an online database that collects information from those affected by all types of frontotemporal degeneration (FTD):
Persons diagnosed, current and former caregivers, family, and friends can join. As a member of the Registry, you can help us advance the science and move faster toward finding treatments and cures. The first step is simple:
NUMBERS HAVE POWER.
JOIN THE REGISTRY.
ADVANCE THE SCIENCE.
NUMBERS HAVE POWER.
JOIN THE REGISTRY.
ADVANCE THE SCIENCE.
Together we can find a cure for ftd
The FTD Disorders Registry is a powerful tool in the movement to create therapies and find a cure. Together we can help change the course of the disease and put an end to FTD.
Your privacy is important! We promise to protect it. We will not share your contact information.
WHAT IS THE FTD DISORDERS REGISTRY?
The Registry is an online database that collects information from those affected by all types of frontotemporal degeneration (FTD):
Persons diagnosed, current and former caregivers, family, and friends can join. As a member of the Registry, you can help us advance the science and move faster toward finding treatments and cures. The first step is simple:
AND NOW WE WORK TOGETHER >
Will you join the community working to end FTD?
WHO CAN JOIN >
Anyone with a connection to FTD disorders and an interest in research is encouraged to join the Registry, including:
- people diagnosed with an FTD disorder
- biological family members
- spouses
- caregivers
- friends
- physicians
- and other healthcare professionals
UPDATES
Alector Announces Results from Phase 3 INFRONT-3 Trial of Latozinemab for FTD-GRN
Alector has announced topline results from its Phase 3 INFRONT-3 trial of latozinemab for FTD-GRN.
Quick Question September 2025 Result:
Life with FTD is about so much more than medical symptoms. To better understand the impact of FTD disorders, our September Quick Question asked …
The Road Ahead: How Registry Data Can Drive Breakthroughs
Progress is possible. See how Registry data can unlock breakthroughs in FTD research just as new treatments are showing progress in other neurological disorders.
Alector Announces Results from Phase 3 INFRONT-3 Trial of Latozinemab for FTD-GRN
Alector has announced topline results from its Phase 3 INFRONT-3 trial of latozinemab for FTD-GRN.
Quick Question September 2025 Result:
Life with FTD is about so much more than medical symptoms. To better understand the impact of FTD disorders, our September Quick Question asked …
Alector Announces Results from Phase 3 INFRONT-3 Trial of Latozinemab for FTD-GRN
Alector has announced topline results from its Phase 3 INFRONT-3 trial of latozinemab for FTD-GRN.
WAYS TO HELP
JOIN US TODAY
Be part of the community working to end FTD. Every voice counts.
PARTICIPATE IN RESEARCH
Support the science for an FTD cure. Sign up here.
SPREAD THE WORD
Invite family and friends to join the growing FTD Registry.
THE FTD REGISTRY IS A PARTNERSHIP OF:
